Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.61 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21568167 | 0.91 | MEN1 (0.60) | LMNAMEN1MAPTKMT2AHTT | |
| SCHEMBL23256883 | 0.91 | DYRK1A (0.66) | LMNAMEN1MAPTKMT2AHTT | |
| SCHEMBL21568323 | 0.90 | DYRK1A (0.65) | LMNAMEN1MAPTKMT2AHTT | |
| SCHEMBL23256870 | 0.88 | DYRK1A (0.70) | LMNAMEN1MAPTKMT2AHTT | |
| SCHEMBL21551996 | 0.87 | DYRK1A (0.61) | LMNAMEN1MAPTKMT2AHTT | |
| SCHEMBL23256871 | 0.86 | SMN1; SMN2 (0.66) | MEN1MAPTKMT2AHTTKDM4E | |
| SCHEMBL21568257 | 0.85 | KDM4E (0.61) | LMNAMEN1MAPTKMT2AHTT | |
| SCHEMBL21568852 | 0.84 | RAB9A (0.67) | LMNAMEN1MAPTKMT2AHTT | |
| SCHEMBL23256551 | 0.84 | DYRK1A (0.60) | LMNAMEN1MAPTKMT2AHTT | |
| SCHEMBL21568163 | 0.83 | CXCR2 (0.59) | LMNAMEN1MAPTKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287098-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2024-08-29 | — | — | US | disclosed |
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2021-04-22 | — | — | US | disclosed |
| WO-2019217509-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | VHL, TP53, NUDT1 | LMNA 2105/4885MEN1 977/4885MAPT 1476/4885 |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | VHL, TP53, NUDT1 | LMNA 2290/4885MEN1 1079/4885MAPT 1587/4885 |
| US-20240287098-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | VHL, TP53, NUDT1 | LMNA 2105/4885MEN1 977/4885MAPT 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.